ZEISS Medical Technology (ZEISS) has received approval from the US Food and Drug Administration (FDA) for its aspheric, monofocal and single-piece C-loop intraocular lens (IOL), the CT LUCIA 621P Monofocal IOL.
The IOL uses the ZEISS Optic Asphericity Concept, which compensates for a range of spherical aberrations caused by different corneal shapes and lens positions.
The IOL also mitigates issues with potential decentration and lens misalignments and delivers optimal visual outcomes.
Nethradhama Super Speciality Eye Hospital Bangalore chairman and managing director Sri Ganesh said: “This is my standard, go-to monofocal lens. It’s one we use routinely in our practice and even for complex cases.
“Since it’s a preloaded lens that is easy to use, it’s very predictable. And the refractive stability is reliable from 15-day post-op to three months, or even one year out.”
The CT LUCIA 621P Monofocal IOL is part of the ZEISS cataract workflow solution portfolio which is aimed at providing optimised visual outcomes for cataract patients.
It is offered in a fully preloaded injector for an intuitive and easy injection.
The design includes an optic-haptic junction and C-loop haptics to enable easy centring while maximising direct capsular contact, thus ensuring stability and a consistent position in the capsular bag.
ZEISS Medical Technology ophthalmology strategic business unit president and digital business unit head Euan S Thomson said: “The CT LUCIA 621P Monofocal IOL is a great example of how our latest ophthalmic innovations are driving efficiency and better patient outcomes in the United States.
“As part of our ZEISS Medical Ecosystem and integrated with other ZEISS cataract workflow solutions, we believe this monofocal IOL will promote better surgical management and help set new standards for cataract patient care.”
The company plans to present the CT LUCIA 621P Monofocal IOL at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) conference, to be held next month in San Diego, California.